AgeX Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized on the 22 nd day of March 2024.
| AGEX THERAPEUTICS, INC. | |
| By: | /s/ Joanne M. Hackett |
| Joanne M. Hackett | |
| Interim Chief Executive Officer |
| Signature | Title | Date |
|---|---|---|
| /s/ Joanne M. Hackett | Interim Chief Executive Officer | March 22, 2024 |
| JOANNE M. HACKETT | (Principal Executive Officer) | |
| /s/ Andrea E. Park | Chief Financial Officer | March 22, 2024 |
| ANDREA E. PARK | (Principal Financial and Accounting Officer) | |
| /s/ Gregory H. Bailey | Director | March 22, 2024 |
| GREGORY H. BAILEY | ||
| /s/ Jean-Christophe Renondin | Director | March 22, 2024 |
| JEAN-CHRISTOPHE RENONDIN | ||
| /s/ Steven Mintz | Director | March 22, 2024 |
| STEVEN MINTZ | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.